Intermediate dose cytarabine plus mitoxantrone is as effective as, but more toxic than, low-dose cytarabine for postremission therapy among older patients with primary acute myeloid leukemia

✍ Scribed by Matt Kalaycio

• Book ID: 114483863
• Publisher: Elsevier Science
• Year: 2002
• Tongue: English
• Weight: 106 KB
• Volume: 3
• Category: Article
• ISSN: 1363-4054
• DOI: 10.1054/ebon.2002.0019